Timing and implications for immune response to vaccine in SARS-CoV-2 breakthrough infections.
Health sciences
Immune response
Immunology
Virology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
19 May 2023
19 May 2023
Historique:
received:
28
08
2022
revised:
25
11
2022
accepted:
18
04
2023
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
ppublish
Résumé
COVID-19 vaccines elicit a strong anti-S antibodies response. We aim to describe antibody titers in peri-vaccination SARS-CoV-2 infections. This is a retrospective longitudinal single-cohort study. Serological tests were performed at the time of the first SARS-CoV-2 vaccine dose (T0) and 60 (T1), 120 (T2), and 240 (T3) days after. The study included 4,682 subjects. Group A had the infection without an anti-S Ig response. Group B and C seroconverted for anti-N Ig between T0 and T1 and between T1 and T2, respectively. Group D was persistently anti-N Ig negative. Group B showed an initial sub-optimal response, reaching the highest titer at T3. Those who received the second dose 120 days after the infection had higher titers compared to those who received it 21 days after the first dose. The immune response depends on the number and the timing of vaccine doses, highlighting the need for a more personalized approach to vaccination.
Identifiants
pubmed: 37152764
doi: 10.1016/j.isci.2023.106716
pii: S2589-0042(23)00793-9
pmc: PMC10122568
doi:
Types de publication
Journal Article
Langues
eng
Pagination
106716Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Lancet Infect Dis. 2020 Dec;20(12):1401-1408
pubmed: 32758438
JAMA. 2021 Jun 22;325(24):2457-2465
pubmed: 33956048
EBioMedicine. 2022 Jan;75:103805
pubmed: 35032961
Front Immunol. 2021 Sep 27;12:728021
pubmed: 34646267
Eur J Cancer. 2022 Jan;160:243-260
pubmed: 34794855
N Engl J Med. 2022 Mar 31;386(13):1207-1220
pubmed: 35172051
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Front Public Health. 2022 Mar 31;10:847384
pubmed: 35433614
Emerg Infect Dis. 2021 Apr;27(4):1220-1222
pubmed: 33522478
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2016 Apr 28;374(17):1635-46
pubmed: 25629663
EBioMedicine. 2021 Aug;70:103539
pubmed: 34391087
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Clin Infect Dis. 2020 Nov 19;71(16):2255-2258
pubmed: 32337590
J Infect Dis. 2013 Aug 1;208(3):418-22
pubmed: 23633407
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Sci Rep. 2022 May 24;12(1):8707
pubmed: 35610464
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Microorganisms. 2021 Feb 25;9(3):
pubmed: 33669151
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
Infez Med. 2020 Ahead of print Jun 1;28(2):133-134
pubmed: 32275253
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
PLoS One. 2018 Jan 12;13(1):e0190940
pubmed: 29329308
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
JAMA. 2021 May 11;325(18):1896-1898
pubmed: 33739374